Abstract: Chemical compounds for the treatment of myeloid neoplasms and solid tumors are described, where the compounds were identified through a screening process assessing the binding affinity of the compounds to a synthesized fragment of Setbp1 protein.

Abstract: The present invention relates to a process for the preparation of arylsulfonylpro-penenitriles. The reaction starting from arylsulfonyl halides is catalyzed by a cat-alyst compound comprising a transition metal. The process is scalable, environ-mentally benign and provides the product in good yield.

Abstract: HSP110 inhibitors bind directly to the nucleotide binding domain of HSP110 and then block the phosphorylation of STAT3, cancer cell growth or MyD88 stability. Aspects involve a compound of formula (I) for use in the treatment of a HSP110-associated cancer, for example colorectal cancer and lymphoma. An examplary compound was tested on a syngeneic model for which mouse colon cancer CT-26 cells were injected into Balb/c mice and on a NOD/SCID model in which mice were implanted with human colorectal cancer HCT116 cells. In those animals bearing a tumor, the compound induced tumor regression that was associated with the inhibition of other HSP110 reported tumorigenic functions (resistance to apoptosis, induction of pro-tumor macrophages). Further, the compound was tested on large B cell lymphoma cell lines (DLBCL) and it was able to alter the interaction between HSP110 and MyD88, which induces a degradation of the oncogene MyD88.

Abstract: The invention relates to a compound of formula (I) wherein A1, A2, X and R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.

Abstract: An methyl 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoate compound, its synthesis, and its use as an antimicrobial agent.

Abstract: This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Abstract: Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.

Abstract: The present invention refers to a process for direct C—H functionalization, the reagents used in the process and the use thereof for the direct C—H functionalization as well as the so-obtained products.

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Abstract: The present invention relates to a laurolactam preparation method and synthesis apparatus, and epoxidation and a rearrangement reaction are performed in the conversion of cyclododecene into cyclododecanone so that the preparation method can synthesize laurolactam having a higher purity with a higher selectivity and in a higher yield than a conventional preparation method.

Abstract: Disclosed is a high yield, high selectivity and high conversion method to produce Dimethyl Carbonate (DMC) from carbon dioxide (CO2) and methanol (MeOH) using optimized concentration of ethylene oxide as water scavenger. The method provides an alternative and optimized solution towards the problem of formation of water in DMC synthesis by reporting optimal feed ratio and scavenger to MeOH feed ratio. The disclosure also discloses an optimal pressure condition that could have significant impact on economy of compression of the feed to the DMC reactor.

Abstract: The invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3 and R4 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as immunostimulatory agents.

Abstract: Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.

Abstract: A 2-(benzo[d]oxazol-2-yl)-N?-(3,5-dichlorobenzoyloxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: An methyl 4-((5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)methyl)benzoate compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Preparations of folate for use in the treatment of eye disorders in the presence of elevated intraocular pressure. Methods of reducing intraocular pressure in a patient having an eye disease.

Abstract: Synthesis of a compound 3,5-dinitro-N-(pyrimidin-2-ylcarbamothioyl)benzamide and its use as an insecticidal agent.

Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

Abstract: Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.